PCVX
Vaxcyte, Inc. Health Care Biological Products, (No Diagnostic Substances) Russell 3000
$62.03Close
$8.1BMarket cap
$40.32 – $73.8252-week range
Nov 3, 2026Next report
Highlights
Strengths
- In a stage-2 uptrend all 8 trend conditions pass
Cautions
- Results soon Nov 3, 2026, in 2 days
Price
Filing Results Screen pick 52-week high and low Adjusted prices
Key figures
Off 12-month high
16%
1wk
up 2.6%
price change
1mo
up 9.0%
price change
12-month return
up 39%
market up 11% ·
its own up 32%
F-score
—
— Not assessed
Altman Z
—
Unknown
P/E
—
price / earnings
PEG
—
P/E / EPS growth
P/B
3.0×
price / book
Earnings yield
down 11.6%
EBIT / enterprise value
Cheaper than
—
of the market · not assessed
Revenue growth
—
year on year
EPS growth
—
latest quarter
Sales growth
—
latest quarter
ROE
0%
return on equity
Free cash margin
—
-$669.3M FCF
D/E
—
long-term debt / equity
Net debt / EBITDA
—
Interest cover
—EBIT / interest
Trade setup
ATR%
5.8%
$3.57 a day · 2×ATR $54.89
RS
77 / 99
vs the universe
Trend
8 / 8
trend template
Relative volume
0.7×
vs 50-day average
Up/down volume
1.17
50 sessions
Implied move
—
no option chain · report Nov 3, 2026
Trend template · 8 of 8
Screen verdict
Did not qualify for any screen.
Warning signs
- Shareholders diluted The share count rose 4.9% over the year, from 125m to 131m shares. Each existing share owns a smaller fraction of the company than it did a year ago.
Last reported
Aug 5, 2026
Last shock
Oct 6, 2026-10% in one session6.2× volumeon an SEC filing-7% since
Financials
- Cash
- Long-term debt
| FY2020Dec 31, 2020 | FY2021Dec 31, 2021 | FY2022Dec 31, 2022 | FY2023Dec 31, 2023 | FY2024Dec 31, 2024 | FY2025Dec 31, 2025 | |
|---|---|---|---|---|---|---|
| Operating income | -$89.6M | -$103.7M | -$232.3M | -$468.0M | -$569.5M | -$923.7M |
| Net income | -$89.2M | -$100,077 | -$223,485 | -$402,266 | -$463,927 | -$766,628 |
| Earnings per share | -$3.02 | -$0.00 | -$0.00 | -$0.00 | -$0.00 | -$0.01 |
| Free cash flow | -$47.8M | -$127.9M | -$176.4M | -$312.9M | -$475.1M | -$669.3M |
| Cash | $386.2M | $69.0M | $834.7M | $397.5M | $387.9M | $174.0M |
| Shareholders' equity | $345.8M | $284.0M | $953.6M | $1.2B | $3.3B | $2.7B |
| Shares outstanding | 51.07m | 53.03m | 79.47m | 95.36m | 124.89m | 131.06m |
Filings
| Filed | Report | Period to | Lag |
|---|---|---|---|
| Aug 5, 2026 | Quarterly ↗ | Jun 30, 2026 | 36d |
| May 6, 2026 | Quarterly ↗ | Mar 31, 2026 | 36d |
| Feb 24, 2026 | Annual ↗ | Dec 31, 2025 | 55d |
| Nov 4, 2025 | Quarterly ↗ | Sep 30, 2025 | 35d |
| Aug 6, 2025 | Quarterly ↗ | Jun 30, 2025 | 37d |
| May 7, 2025 | Quarterly ↗ | Mar 31, 2025 | 37d |
| Feb 25, 2025 | Annual ↗ | Dec 31, 2024 | 56d |
| Nov 5, 2024 | Quarterly ↗ | Sep 30, 2024 | 36d |
| Aug 6, 2024 | Quarterly ↗ | Jun 30, 2024 | 37d |
| May 8, 2024 | Quarterly ↗ | Mar 31, 2024 | 38d |
| Feb 27, 2024 | Annual ↗ | Dec 31, 2023 | 58d |
| Nov 6, 2023 | Quarterly ↗ | Sep 30, 2023 | 37d |
Current reports
| Filed | Disclosed |
|---|---|
| Oct 9, 2026 | Material agreement · New obligation · Other events ↗ |
| Oct 5, 2026 | Regulation FD · Other events ↗ |
| Sep 3, 2026 | Director or officer change · Regulation FD ↗ |
| Aug 5, 2026 | Results ↗ |
| Jul 15, 2026 | Director or officer change ↗ |
| Jun 23, 2026 | Director or officer change ↗ |
| Jun 16, 2026 | Shareholder vote ↗ |
| May 6, 2026 | Results ↗ |
| Feb 24, 2026 | Results ↗ |
| Feb 24, 2026 | Other events ↗ |
| Feb 2, 2026 | Other events ↗ |
| Dec 19, 2025 | Director or officer change ↗ |